Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Nicholson

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Cancer Immunology, Immunotherapy : CII|May 6, 2004
A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancerSteve Nicholson, C C Bomphray, H Thomas, et al.
The Journal of Investigative Dermatology|January 11, 2013
Plasma microRNA-21 is associated with tumor burden in cutaneous melanomaGerald Saldanha, Linda Potter, Priya Shendge, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
The Lancet. Oncology|September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen, Heikki Joensuu, Paul D Nathan, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
Standardization of radiation therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)Sian Cooper, Steve Nicholson, Juanita Crook, et al.
British Journal of Cancer|October 21, 2021
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penisSteve Nicholson, Holly Tovey, Tony Elliott, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Immunology, Immunotherapy : CII|May 6, 2004
A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancerSteve Nicholson, C C Bomphray, H Thomas, et al.
The Journal of Investigative Dermatology|January 11, 2013
Plasma microRNA-21 is associated with tumor burden in cutaneous melanomaGerald Saldanha, Linda Potter, Priya Shendge, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2010
A phase 2 study of vatalanib in metastatic melanoma patientsNatalie Cook, Bristi Basu, Swethajit Biswas, et al.
The Lancet. Oncology|September 11, 2012
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trialTim Eisen, Heikki Joensuu, Paul D Nathan, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
Standardization of radiation therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT)Sian Cooper, Steve Nicholson, Juanita Crook, et al.
British Journal of Cancer|October 21, 2021
VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penisSteve Nicholson, Holly Tovey, Tony Elliott, et al.
The Lancet. Oncology|April 22, 2014
Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 studyPippa G Corrie, Andrea Marshall, Janet A Dunn, et al.
Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2014
Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers InitiativeJan Bogaerts, Matthew R Sydes, Nicola Keat, et al.
Pageof 2